US-based pharmaceutical firm Apricus Biosciences has received national phase approval from the Spanish Agency for Medicines and Health Products (AEMPS) for Vitaros, a topical on-demand treatment for erectile dysfunction (ED).

Following broad approval by European health authorities in June 2013, Apricus secured a total of ten national phase approvals for Vitaros, including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the UK.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company has an exclusive partnership in place with Recordati for the commercialisation of the drug in Spain, Russia, Turkey, Ireland and certain other European and African countries.

"Vitaros will become the first new ED product in nearly a decade, and has potential to help a large number of patients who do not respond well to existing therapies, or who are intolerant to the systemic effects of PDE-5 inhibitors."

Apricus chief executive officer Richard Pascoe said: "We look forward to the first launch of Vitaros in the United Kingdom, and in other countries where Vitaros is approved by our commercial partners."

In June 2013, Apricus secured marketing application approval for Vitaros through the European DCP, which the company filed its application under for marketing approval designating the Netherlands as the reference member state (RMS) on behalf of nine other European concerned member states (CMS) participating in the procedure.

See Also:

The company said that it has now received national phase approval for all ten of the member states.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the launch, Vitaros will become the first new ED product in nearly a decade, and has potential to help a large number of patients who do not respond well to existing therapies, or who are intolerant to the systemic effects of PDE-5 inhibitors.

The drug is currently partnered in major markets such as Takeda in the UK, Sandoz in Germany, Switzerland and certain countries in Northern Europe, Bracco in Italy, Majorelle in France, Monaco and certain African countries, Recordati in Spain, Russia, Turkey, Ireland and certain other European and African countries, and Abbott in Canada.

Apricus’s existing commercialisation partners are preparing for the launch of Vitaros in their respective territories throughout 2014.